This activity is provided by Paradigm Medical Communications, LLC.
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Interstitial lung disease (ILD) presents challenges for pulmonologists, radiologists, and pathologists, who must discern among more than 100 other potential ILDs and non-ILD mimickers via scrupulous testing and multidisciplinary collaboration to arrive at an accurate and timely diagnosis. Early detection has become more critical than ever, with the US Food and Drug Administration’s (FDA) first-ever approval of treatments (antifibrotics) for idiopathic pulmonary fibrosis (IPF), a fatal and relentlessly progressive fibrosing ILD. While these agents offer an unprecedented opportunity to slow IPF disease progression, guidance on the practical aspects of their use, including when to start prescribing them, is needed. Research is underway to determine whether nintedanib, an antifibrotic agent indicated for IPF, could also benefit patients with progressive fibrosing (PF)-ILD or systemic sclerosis ILD (SSc-ILD), a connective tissue disease-related ILD (CTD-ILD), for which nintedanib was granted orphan drug status in 2016. With new data emerging, and expanded indications possible soon, education on ILD management is a topic of timeliness and relevance to many healthcare professionals.
Table of Contents
Introduction: The Challenges and Importance of Early ILD Diagnosis
Evaluating the Nonspecific Symptoms of ILD: Guideline-based Strategies for Earlier Detection
Comprehensive Care of the IPF Patient: Therapeutic Options and Shared Decision-making
This activity has been designed to address the educational needs of pulmonologists, radiologists, and pathologists. The activity may also benefit primary care physicians, PAs, nurse practitioners, nurses, pharmacists, fellows, residents, and other allied healthcare providers who care for patients with interstitial lung disease.
Upon proper completion of this activity, participants should be better able to:
Evaluate patients with symptoms of interstitial lung disease according to guideline-based algorithms to distinguish between idiopathic pulmonary fibrosis and connective tissue disease-related interstitial lung disease.
Individualize antifibrotic therapy for appropriate patients with idiopathic pulmonary fibrosis, based on current evidence.
Outline evidence-based information about interstitial lung disease course and treatment to share with patients at the time of diagnosis.
Conflict Of Interest Disclosure Policy
Paradigm Medical Communications, LLC, has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Faculty Presenter Mark J. Hamblin, MD, FCCP Assistant Professor Director of KU ILD & Rare Lung Disease Clinic Division of Pulmonary and Critical Care Medicine University of Kansas Health Care System Kansas City, KS
Dr. Hamblin discloses the following: Grant/Research Support: Biogen; Boehringer Ingelheim Pharmaceuticals, Inc; FibroGen, Inc.; Genentech, Inc.; Global Blood Therapeutics, Inc.; Promedior, Inc. Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc
Steering Committee David J. Lederer, MD, MS (Chair) Associate Professor of Medicine and Epidemiology Division of Pulmonary, Allergy, and Critical Care Medicine Co-Director, Interstitial Lung Disease Program Columbia University Medical Center New York, NY
Dr. Lederer discloses the following: Grant/Research Support: Boehringer Ingelheim Pharmaceuticals, Inc; FibroGen, Inc. Retained Consultant: FibroGen, Inc.; Galapagos NV; Global Blood Therapeutics, Inc.; Roche; Sanofi Genzyme; Veracyte, Inc.
Erica L. Herzog, MD, PhD Associate Professor Department of Internal Medicine Section of Pulmonary, Critical Care, and Sleep Medicine Director, Interstitial Lung Disease Center of Excellence Yale School of Medicine New Haven, CT
Dr. Herzog discloses the following: Grant/Research Support: Bristol-Myers Squibb Company; sanofi-aventis U.S. LLC Retained Consultant: Boehringer Ingelheim Pharmaceuticals, Inc Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc
Rebecca C. Keith, MD Assistant Professor Department of Medicine Division of Pulmonary, Critical Care and Sleep Medicine Interstitial Lung Disease Program Sarcoidosis Program Autoimmune Lung Center National Jewish Health Denver, CO
Dr. Keith discloses the following: Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.
Contributing Faculty Jay S. Leb, MD Assistant Professor of Radiology Department of Radiology Columbia University Medical Center New York, NY
Dr. Leb discloses the following: Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.
Julie Porcelli, MSN, RN, CNL Program Coordinator Division of Pulmonary, Allergy and Critical Care Medicine Columbia University Medical Center New York, NY
Ms. Porcelli discloses the following: Speakers Bureau: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc.
Anjali Saqi, MD, MBA Professor Department of Pathology and Cell Biology Columbia University Medical Center New York, NY
Dr. Saqi discloses the following: Grant/Research Support: Columbia-Coulter Translational Research Partnership; FAR-ILD Honoraria: Boehringer Ingelheim Pharmaceuticals, Inc; Genentech, Inc. Retained Consultant: Boston Scientific Corporation; Genentech, Inc.
Patient Faculty Robert Byrnes Parsippany, NJ
Mr. Byrnes has no financial relationships to disclose.
Accredited Provider Disclosure
Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.
Independent peer reviewer has no financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Paradigm Medical Communications, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Paradigm Medical Communications, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC, activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
To receive a CME certificate of participation, participants must:
Follow the "Start Activity" button to go to the Paradigm Medical Communications website, where you will complete the pre-activity assessment.
View the online activity in its entirety.
Complete and submit the online post-activity assessment and evaluation.
A certificate of participation will be available for download/printing immediately following your successful completion of the post-activity assessment and evaluation. Your certificate will be saved on the Paradigm Medical Communications website and will not be available in your myCME CME History.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
Disclaimer The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the Faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.
Security/safeguarding personal information This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC, to continuously improve the learning experience.
Paradigm Medical Communications, LLC, does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.